Fund of the Week: Curie.Bio
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Company of the week: Elevara Medicines
Company Overview and Corporate Structure
Elevara Medicines Ltd. is a London-based clinical-stage biotechnology company focused on innovative therapies for rheumatoid
Bankrupt Biotech Royalty Auctions: Navigating Royalty Sales
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Royalties Unstacked: Allocating the Proceeds in Combination Therapies
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Negative Pledge Covenants in Pharmaceutical Credit Agreements
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
The Weekly Term Sheet (43)
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Volatility Laundering: Smoothing Out Risk or Sweeping It Under the Rug?
A Calm Surface Hiding Choppy Seas
Imagine a portfolio that glides through market turmoil with uncanny smoothness, scarcely registering a
Fund of the week: Nvidia's NVentures
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
Company of the Week: Lila Sciences – A Red and Blue Team Analysis
Introduction
Lila Sciences is a cutting-edge startup aiming to revolutionize scientific research through artificial intelligence and automation. Founded in 2023
Anthropic's Claude in Life Sciences: Accelerating Biotech and Healthcare R&D
Anthropic launched "Claude for Life Sciences" in October 2025, introducing new AI capabilities tailored to biotechnology and pharmaceutical
